Long-term management of adenomyosis with a gonadotropin-releasing hormone agonist: a case report.
Leuprolide acetate was used to produce a constant hypoestrogenic environment in a young patient with histologically confirmed adenomyosis. Conservative medical therapy was initiated because of the patient's complaint of severe dysmenorrhea coupled with her strong desire for uterine conservation. The initial daily subcutaneous dose was eventually converted to monthly intramuscular depot formulation for patient convenience. A dramatic therapeutic response was observed with each course of therapy. This included a marked reduction in uterine size, amenorrhea, and complete resolution of pelvic pain. Cyclic use of an OC agent following LA was associated with a return of symptoms and uterine growth. The patient did, in fact, conceive immediately on cessation of analogue therapy.
Nelson
J R
JR
Pennsylvania Hospital, Department of Obstetrics and Gynecology, Pennsylvania.
Corson
S L
SL
D000328:Adult; D003276:Contraceptives, Oral / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004715:Endometriosis / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007813:Laparotomy; D016729:Leuprolide / Q000627:therapeutic use*; D011182:Postoperative Care; D013997:Time Factors; D017329:Triptorelin Pamoate / Q000031:analogs & derivatives*
D003276:Contraceptives, Oral; D003692:Delayed-Action Preparations; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; C019176:Tryptal; D016729:Leuprolide